Dementia Clinical Trial
Official title:
A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults
Verified date | April 2017 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Quetiapine, a second generation antipsychotic, is only available as oral tablets. However, topical and rectal formulations have been produced in compounding pharmacies. There is no data available suggesting that topical or rectal formulations provide serum levels similar to oral medication. In the clinical setting, when oral administration of quetiapine is not possible (for example, when a patient is extremely ill physically or mentally or both), clinicians and pharmacists have collaborated in such cases and have at times had to administer quetiapine compounded in other dosage formulations such as rectal or topical formulations. Despite clinical effectiveness of these other formulations, there are no available studies that have investigated blood levels of the drug other than the oral form. The investigators are therefore designing this pharmacokinetic study to evaluate the the systemic absorption of quetiapine in oral, rectal and topical formulations. If the investigators are able to demonstrate detectable levels from rectal and topical quetiapine formulations compared to the oral form, this knowledge will enhance clinical psychiatric practice by providing a more broad route of administration for quetiapine which is a commonly used drug for psychiatric symptoms.
Status | Completed |
Enrollment | 10 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy adult volunteers (18-65 years old) willing to undergo a general health screen consisting of blood pressure, heart rate, respiratory rate, height, weight, temperature, and electrocardiogram will be identified. - The below parameters must be met to be consider an adult healthy to volunteer for inclusion in this study: - Blood pressure less than 160/99 mmHg and greater than 105/50 mmHg - Heart rate between 50-100 beats per minutes - Respiratory rate between 10-30 breaths per minute - Temperature between 34 °C and 37.5°F - Corrected QT interval of < 470 msec - Liver function tests less than 1.5 times the upper limit of normal - Estimated creatinine clearance (estimated by Cockcroft Gault formulation) greater than 60 mL/min - Female participants will complete a urine pregnancy test that must result in a negative finding Exclusion: 1. Allergy to quetiapine, Lipoderm or polyethylene glycol 2. Currently taking quetiapine 3. Pregnant, planning to become pregnant or breast feeding 4. Over or under 30% of ideal body weight 5. History of or active cardiovascular disease (except hypertension meeting the inclusion criteria for blood pressure), severe kidney disease (i.e. needing dialysis), or liver disease 6. History of schizophrenia, bipolar disorder, substance use disorders (but excluding nicotine use disorders and stable unipolar depression (See below)) 7. Unstable unipolar depression, defined as hospitalization for depression within 1 year or changes to an antidepressant regimen within 6 months 8. History of seizure or seizure disorder 9. Parkinson's disease, Huntington's disease, tardive dyskinesia or other diagnosed movement disorder 10. History of/or active hematologic/oncologic illness 11. Dementia 12. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome 13. History of organ transplant 14. History of gastric bypass 15. Contraindications for suppository administration 16. With Ostomy, chronic diarrhea 17. Diabetes, type 1 or type 2 18. Prolong corrected QT interval (>470 msec) or history of congenital long QT syndrome 19. Open wound(s) or unhealed wound(s) at topical medication application site (anterior forearm) 20. Active or latent tuberculous and currently prescribed pharmacotherapy treatments 21. Currently prescribed or taken with in the last 7 days, medications which have a known interaction with quetiapine or compound the risk of adverse events associated with quetiapine: - QTc prolonging medications: - Antipsychotics - Vaughan Williams Class IA, IB, IC, III antiarrhythmics - Anti-infective agents (excluding topical agents, oral penicillins, oral cephalosporins) - Antiemetics - Methadone - Cisapride - Cimetidine - Divalproex sodium/valproic acid - Tetrabenazine - Solifenacin - Tricyclic antidepressants - Tizanidine - Fingolimod - Increase quetiapine concentrations, not previously mentioned - Paroxetine - Fluoxetine - Fluvoxamine - Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) - Tamoxifen - Cyclosporin (excluding ophthalmic formulation) - Nefazodone - Decrease quetiapine levels, not previously mentioned - Bosentan - Carbamazepine - Glucocorticoids - Modafinil - Primidone - St. John's wort - Barbiturates - Phenytoin 22. Vulnerable populations will be excluded (i.e. prisoners, wards of the state, emancipated minors, children, pregnant women) 23. Inability to receive telephone calls for the purpose of post-intervention follow-up 24. Inability or unwillingness of individual to give written informed consent 25. Non-English speaking populations |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum quetiapine levels after topical application (Visit 1) | Areas under the curve versus time | 8 hours | |
Primary | Serum quetiapine levels after oral administration (Visit 2) | Areas under the curve versus time | 8 hours (no sooner than 72 hours from end of visit 1) | |
Primary | Serum quetiapine levels after rectal administration (Visit 3) | Areas under the curve versus time | 8 hours (no sooner than 72 hours from end of visit 2) | |
Secondary | Serum quetiapine levels after topical administration over 24 hours | Topical quetiapine applied every 4 hours for 24 hours | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05686486 -
Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes
|
N/A | |
Terminated |
NCT05451693 -
Outreach-ER: A Dementia Care Intervention Program
|
||
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Enrolling by invitation |
NCT06040294 -
Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills
|
N/A | |
Completed |
NCT05114187 -
An Internet-Based Education Program for Care Partners of People Living With Dementia
|
N/A | |
Recruiting |
NCT06322121 -
Vascular Aspects in Dementia: Part 2
|
||
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT04426838 -
Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad
|
N/A | |
Recruiting |
NCT03462485 -
Pilot Study of the Effects of Playing Golf on People With Dementia
|
N/A | |
Active, not recruiting |
NCT03677284 -
Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia
|
N/A | |
Completed |
NCT03849937 -
Changing Talk Online (CHATO) Study
|
N/A | |
Recruiting |
NCT06284213 -
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
|
||
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Completed |
NCT04571697 -
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT05684783 -
Dementia Champions in Homecare
|
||
Completed |
NCT03147222 -
Function Focused Care: Fracture Care at Home
|
N/A |